Article

Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma

2024-08-06

Abstract excerpt

Purpose: This study explores the potential of preclinical in vitro cell line response data and computational modeling in identifying optimal dosage requirements of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma treatment. Our research is motivated by the critical role of drug combinations in enhancing anti-cancer responses and the need to close the knowledge gap around selecting effective dos...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b00e02bc-49b1-5c3f-a474-27890b26abc0
DOI: 10.1101/2024.08.02.606432

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaDOI 10.1101/2024.08.02.606432Read

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.Semantic proximity Read

High-throughput drug screening in advanced pre-clinical 3D melanoma models identifies potential first-line therapies for NRAS-mutated melanomaSemantic proximity Read

Understanding the potential benefits of adaptive therapy for metastatic melanomaSemantic proximity Read

Multiobjective Optimization Identifies Cancer-Selective Combination TherapiesSemantic proximity Read

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity Read

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read

Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.Semantic proximity Read

Dissecting targeted therapy resistance: Integrating models to quantify environment mediated drug resistanceSemantic proximity Read

Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.Semantic proximity Read

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.Semantic proximity Read

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Semantic proximity Read

Overcoming Resistance to BRAF <sup>V600E</sup> Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network AlterationsSemantic proximity Read